Clinical Trial: A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age
Brief Summary: The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.
Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.
Current Primary Outcome: Neutralizing antibodies to mumps at 6 weeks postvaccination [ Time Frame: 6 weeks postvaccination ]
Original Primary Outcome:
Current Secondary Outcome: Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination [ Time Frame: 6 weeks and 1 year postvaccination ]
Original Secondary Outcome:
Information By: Merck Sharp & Dohme Corp.
Dates:
Date Received: September 22, 2004
Date Started: February 1999
Date Completion:
Last Updated: October 22, 2015
Last Verified: October 2015